A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer (NCT02138734)

🧪 Interventions in This Study

• BCG (50mg/instillation) + N-803 (400 μg/instillation) (BIOLOGICAL)
• BCG (50mg/instillation) (BIOLOGICAL)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (108 Sites)

Showing the first 25 of 108 sites.

• University of Alabama at Birmingham — Birmingham, Alabama
• Alaska Clinical Research Center — Anchorage, Alaska
• Mayo Clinic — Phoenix, Arizona
• Center for Neurosciences — Tucson, Arizona
• Arkansas Urology — Little Rock, Arkansas
• Hoag Memorial Hospital Presbyterian — Irvine, California
• University of Southern California — Los Angeles, California
• UCLA Department of Urology — Los Angeles, California
• University of California, Irvine Medical Center — Orange, California
• University of California, Davis — Sacramento, California
• Golden State Urology — Sacramento, California
• University of California San Diego — San Diego, California
• Skyline Sherman Oaks — Sherman Oaks, California
• Skyline Urology — Torrance, California
• Eastern Connecticut Hematology & Oncology Associates — Norwich, Connecticut
• Memorial Healthcare System — Hollywood, Florida
• Mayo Clinic — Jacksonville, Florida
• Advanced Urology Institute — Oxford, Florida
• Clinical Research Center of Florida — Pompano Beach, Florida
• Florida Urology Partners — Riverview, Florida
• Moffitt Cancer Center — Tampa, Florida
• Emory University — Atlanta, Georgia
• Georgia Urology — Atlanta, Georgia
• University of Hawaii Cancer Center — Honolulu, Hawaii
• Associated Urological Specialists — Chicago, Illinois

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Non-muscle Invasive Bladder Cancer

• Study of CG0070 After Transurethral Resection in Patients With IR NMIBC — Tampa, Florida
• A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer — Tucson, Arizona
• Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention — Dallas, Texas
• A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer — Tampa, Florida
• Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment — Basking Ridge, New Jersey

Explore by condition: All Non-muscle Invasive Bladder Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.